Health Care

Insider sell‑to‑cover by Vera Therapeutics’ COO shows routine RSU tax compliance; investors should focus on upcoming clinical milestones, not stock pressure.

ProMIS Neurosciences insider buying surge signals confidence in PMN310 breakthrough—watch the 60‑day post‑milestone window for a potential price rebound.

Explore how iRhythm’s Chief Accounting Officer’s 10b5‑1 sale signals executive strategy and what it means for investors’ next steps.

Insider sales at Exagen are tax‑driven, not a red flag—investors can still see long‑term value amid routine portfolio moves.

Insider sales at Tempus AI hint at a strategic shift—investors should watch for upcoming moves that could reshape the AI diagnostics company’s valuation.

Teleflex insider buying signals confidence amid volatility, hinting at value potential for investors.

Insider sale by Scholar Rock’s chief scientist shows a slight dip and strategic portfolio shift—an insight into leadership confidence and future valuation risks.

Insider trading shows Xeris Biopharma’s leadership remains bullish, with Nguyen Anh Tu’s recent sell‑off a tactical move, not a loss of confidence, as the company pushes its injectables platform toward launch.

Insider sales at Artivion reveal routine tax‑covering moves, not confidence drops—key for investors to gauge stability amid high P/E and pipeline growth.

Alkermes insider activity: EVP David Gaffin’s latest share trades reveal cautious confidence amid the company’s Avadel acquisition and potential upside.